• Anlotinib and VEGFR2-Driven Tumor Angiogenesis

  2026-09-21

  The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor whose antitumor activity is driven primarily by suppression of tumor-associated angiogenesis. Its integrated biochemical, endothelial, ex vivo vessel, and xenograft experiments show why vascular selectivity can produce strong efficacy while limiting reliance on direct tumor-cell cytotoxicity.

• Z-DEVD-FMK in Mechanistic Apoptosis Assays

  2026-09-21

  Z-DEVD-FMK is a cell-permeable caspase-3 inhibitor that can turn apoptosis assays into mechanistic experiments. This article uses graphene-induced melanoma apoptosis to show how paired pathway readouts, calpain awareness, and rigorous controls improve interpretation.

• Anlotinib in Desmoplastic Small Round Cell Tumor

  2026-09-20

  A 2019 case report described disease control with anlotinib in metastatic intra-abdominal desmoplastic small round cell tumor after surgery and chemotherapy. The report is notable as an early clinical signal for applying a multi-target tyrosine kinase inhibitor to a rare, aggressive sarcoma, while its single-patient design limits conclusions about efficacy and survival.

• LINC02870 Drives SNAIL Translation in Liver Cancer

  2026-09-19

  The reference study identifies LINC02870 as a potentially oncogenic long non-coding RNA that is enriched in hepatocellular carcinoma, particularly HBV-positive disease. Its central mechanistic contribution is linking LINC02870 to EIF4G1-dependent enhancement of SNAIL translation, providing a molecular explanation for increased HCC growth, migration, invasion, and poor prognosis.

• MLN2238: Proteasome β5 Inhibitor Workflows

  2026-09-19

  MLN2238 enables controlled chymotrypsin-like proteasome inhibition for apoptosis, proteotoxic-stress, multiple myeloma, lymphoma, and drug-resistance studies. Its reversible β5 activity also supports time-resolved experiments connecting proteasome dysfunction with ROS, JNK, and CREB signaling.

• Anlotinib for Desmoplastic Small Round Cell Tumors

  2026-09-18

  This case report describes the first reported clinical use of anlotinib in metastatic intra-abdominal desmoplastic small round cell tumor, with substantial lymph-node reduction after four treatment cycles and continued disease control during maintenance therapy. The findings are hypothesis-generating rather than confirmatory, but they provide a clinically relevant rationale for studying multi-target tyrosine kinase inhibition in a rare tumor with limited standardized treatment options.

• Optimized hGBA1 mRNA for Gaucher Disease Therapy

  2026-09-17

  The reference study engineered human GBA1 mRNA through untranslated-region, codon, and poly(A)-tail optimization to increase glucocerebrosidase expression and durability. Its cellular and mouse experiments support mRNA–lipid nanoparticle delivery as a preclinical strategy for restoring lysosomal enzyme function, while also identifying the assay and biodistribution questions that remain before translation.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-09-17

  Anlotinib hydrochloride combines nanomolar activity across VEGFR2, PDGFRβ, and FGFR1 with measurable effects in migration, tube-formation, and ERK readouts. This article turns that profile into a concentration-resolved workflow for mechanism-led angiogenesis studies and translational cancer research.

• Caveolin-1, Cholesterol, and MASLD Progression

  2026-09-17

  The reference study identifies Caveolin-1 (CAV1) as a regulator of hepatic cholesterol homeostasis that limits endoplasmic reticulum stress and pyroptosis during metabolic dysfunction-associated steatotic liver disease. By combining CAV1-deficient mice, transcriptomics, human liver samples, and in vitro experiments, it connects altered cholesterol transport through FXR/NR1H4 and ABCG5/ABCG8 with disease progression and suggests practical avenues for integrated biochemical and membrane-imaging studies.

• Anlotinib Hydrochloride for Angiogenesis Assays

  2026-09-16

  Build mechanism-led angiogenesis experiments around receptor phosphorylation, endothelial phenotypes, and ERK pathway readouts. This guide connects practical migration and tube-formation workflows with translational evidence from a rare tumor case report while emphasizing assay controls and troubleshooting.

• Separating Growth Inhibition from Cell Killing in Cancer

  2026-09-15

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture different components of anticancer drug response. Its central implication is practical: cancer research assays should evaluate growth inhibition, cell death, and their timing as related but noninterchangeable outcomes.

• Fluoxetine HCl: Translational Research Workflows

  2026-09-15

  Fluoxetine HCl supports both defined serotonergic receptor assays and translational models of motivation, allowing researchers to separate acute signaling effects from persistent developmental phenotypes. This guide connects solvent preparation, 5-HT2C workflows, and progressive-ratio behavior with practical troubleshooting and assay-selection strategies.

• Apicidin: Selective HDAC Inhibition and Research Use

  2026-09-14

  Apicidin is a fungal histone deacetylase inhibitor with a product-reported biochemical preference for HDAC3 over HDAC6. Evidence supports its use as an anti-proliferative and epigenetic research tool, while recent oocyte findings define important reproductive-toxicity limits.

• Protease Inhibitor Cocktail: EDTA-Free Lab Guide

  2026-09-14

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic degradation during protein extraction and downstream analysis. It is suited to Western blotting, co-immunoprecipitation, pull-down, phosphorylation, and kinase workflows, but is not a substitute for EDTA when metal-ion chelation is required or when DMSO is incompatible.

• 2X Taq PCR Master Mix for Plant Virus Workflows

  2026-09-13

  Build a practical molecular confirmation workflow around a dye-integrated reagent for genotyping, cloning, and plant-virus testing. This guide connects field-image screening with PCR-based follow-up while showing where direct gel loading, TA cloning, and careful optimization add value.

8486 records 3/566 page Previous Next 12345 下5页 Last page